GlassScriptPhysician profile
Anne L Cox
NPI 1467428268
$14,122.06
in general payments reported to CMS, 2019-2025
31 companies · $770 in 2025
The $770 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,074 · 2020: $1,048 · 2021: $2,240 · 2022: $2,263 · 2023: $2,676 · 2024: $3,051 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,397 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,396.75 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,326.01 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,262.88 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,176.45 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,149.95 | 2019-2025 | Rexulti |
| Alkermes, INC. | $1,053.65 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $1,012.65 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $913.27 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $850.58 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $756.06 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $619.14 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $541.06 | 2019-2024 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $526.28 | 2019-2025 | Ingrezza |
| Bausch Health US, LLC | $460.35 | 2019-2024 | Aplenzin, Wellbutrin |
| Allergan, INC. | $411.83 | 2019-2020 | |
| Corium, LLC | $411.18 | 2021-2024 | Azstarys, Azstarys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $370.03 | 2019-2025 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $332.75 | 2022-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $130.12 | 2019-2022 | |
| Eisai INC. | $121.01 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $111.18 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $109.95 | 2022-2024 | Quviviq |
| Shire North American Group INC | $93.59 | 2019 | |
| Ironshore Pharmaceuticals INC. | $87.47 | 2019-2021 | |
| Almatica Pharma LLC | $86.84 | 2022-2025 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $71.19 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $40.62 | 2019-2020 | |
| Alfasigma USA, INC. | $22.39 | 2020 | |
| Gilead Sciences, INC. | $21.14 | 2019 | |
| Livanova USA, INC. | $19.42 | 2022 | |
| Vertical Pharmaceuticals, LLC | $18.06 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.